HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mukherjee, J. Articles by Casadevall, A. Search for Related Content PubMed PubMed Citation Articles by Mukherjee, J. Articles by Casadevall, A. Pubmed/NCBI databases Substance via MeSH

Monoclonal Antibodies Reveal Additional Epitopes of Serotype D Cryptococcus neoformans Capsular Glucuronoxylomannan that Elicit Protective Antibodies¹

Jean Mukherjee^2,*, Thomas R. Kozel and Arturo Casadevall^*,

^* Division of Infectious Diseases, Department of Medicine, and Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; and Department of Microbiology, University of Nevada School of Medicine, Reno, NV 89557

Epitope specificity and isotype influence mAb efficacy against Cryptococcus neoformans; however, the relative contribution of each attribute is poorly understood. To date, only mAbs that recognize two epitopes of capsular glucuronoxylomannan (GXM), defined by the IgG1 mAbs 2H1 and E1, consistently mediate protection against C. neoformans. The role of epitope specificity was further examined using six additional IgG1 mAbs and serotype D C. neoformans ATCC 24067. mAbs 3C2, 439, and 471 recognize the 2H1 epitope, whereas mAbs 339, 1255, and 302 recognize two separate epitopes. mAbs 3C2, 439, and 471 competed for GXM with the IgA mAb 18G9, a 2H1 mAb family member, whereas mAbs 302, 339, and 1255 did not. Each mAb bound GXM similarly, as determined by agglutination, direct Ag binding, Ag inhibition, and indirect capsular immunofluorescence assays. mAb apparent affinity constants for GXM ranged from 5 to 26 x 10⁷ M^-1 with mAb 1255 > 3C2 > 339 > 439 > 471 > 302. Each mAb significantly prolonged survival (p < 0.05); the average survival times of control and mice passively immunized with mAbs 3C2, 302, 339, 439, 471, and 1255 were 10.8, 36.6, 33, 25.5, 24.9, 17, and 22.6 days, respectively. Although each mAb enhanced J774.16 cell fungicidal activity, differences were observed in the ability of each mAb to facilitate attachment and ingestion of cryptococci. These results indicate 1) two additional epitope specificities associated with mAb efficacy, 2) differences in opsonic and protective efficacy for IgG1 anti-GXM mAbs, 3) an association between affinity and protective efficacy, and 4) additional support for association between an annular indirect capsular immunofluorescence pattern and mAb efficacy.

This article has been cited by other articles:

				H. Tian, S. Weber, P. Thorkildson, T. R. Kozel, and L.-a. Pirofski Efficacy of Opsonic and Nonopsonic Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibodies against Intranasal Challenge with Streptococcus pneumoniae in Mice Infect. Immun., April 1, 2009; 77(4): 1502 - 1513. [Abstract] [Full Text] [PDF]

				K. Datta, A. Lees, and L.-a. Pirofski Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan Clin. Vaccine Immunol., August 1, 2008; 15(8): 1176 - 1187. [Abstract] [Full Text] [PDF]

				R. W. Maitta, K. Datta, Q. Chang, R. X. Luo, B. Witover, K. Subramaniam, and L.-a. Pirofski Protective and Nonprotective Human Immunoglobulin M Monoclonal Antibodies to Cryptococcus neoformans Glucuronoxylomannan Manifest Different Specificities and Gene Use Profiles Infect. Immun., August 1, 2004; 72(8): 4810 - 4818. [Abstract] [Full Text] [PDF]

				O. Zaragoza and A. Casadevall Antibodies Produced in Response to Cryptococcus neoformans Pulmonary Infection in Mice Have Characteristics of Nonprotective Antibodies Infect. Immun., July 1, 2004; 72(7): 4271 - 4274. [Abstract] [Full Text] [PDF]

				D. C. McFadden and A. Casadevall Unexpected Diversity in the Fine Specificity of Monoclonal Antibodies That Use the Same V Region Gene to Glucuronoxylomannan of Cryptococcus neoformans J. Immunol., March 15, 2004; 172(6): 3670 - 3677. [Abstract] [Full Text] [PDF]

				R. W. Maitta, K. Datta, A. Lees, S. S. Belouski, and L.-a. Pirofski Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice Infect. Immun., January 1, 2004; 72(1): 196 - 208. [Abstract] [Full Text] [PDF]

				D. O. Beenhouwer, S. Shapiro, M. Feldmesser, A. Casadevall, and M. D. Scharff Both Th1 and Th2 Cytokines Affect the Ability of Monoclonal Antibodies To Protect Mice against Cryptococcus neoformans Infect. Immun., October 1, 2001; 69(10): 6445 - 6455. [Abstract] [Full Text] [PDF]

				A. Nakouzi, P. Valadon, J. Nosanchuk, N. Green, and A. Casadevall Molecular Basis for Immunoglobulin M Specificity to Epitopes in Cryptococcus neoformans Polysaccharide That Elicit Protective and Nonprotective Antibodies Infect. Immun., May 1, 2001; 69(5): 3398 - 3409. [Abstract] [Full Text] [PDF]

				R. Fleuridor, A. Lees, and L.-a. Pirofski A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with Cryptococcus neoformans Infection J. Immunol., January 15, 2001; 166(2): 1087 - 1096. [Abstract] [Full Text] [PDF]

				D. A. Schaefer, B. A. Auerbach-Dixon, and M. W. Riggs Characterization and Formulation of Multiple Epitope-Specific Neutralizing Monoclonal Antibodies for Passive Immunization against Cryptosporidiosis Infect. Immun., May 1, 2000; 68(5): 2608 - 2616. [Abstract] [Full Text] [PDF]

				T. C. MacGill, R. S. MacGill, A. Casadevall, and T. R. Kozel Biological Correlates of Capsular (Quellung) Reactions of Cryptococcus neoformans J. Immunol., May 1, 2000; 164(9): 4835 - 4842. [Abstract] [Full Text] [PDF]